Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. - Jahn, A.; Rump, A.; Widmann, T.J.; Heining, C.; Horak, P.; Hutter, B.; Paramasivam, N.; Uhrig, S.; Gieldon, L.; Drukewitz, S.; Kübler, A.; Bermudez, M.; et al. (Annals of Oncology, 2022)